Table 4.
—Relationship Between Cotinine (ng/mL) as a Continuous Variable and Obstetric and Neonatal Outcomes in the Randomized Clinical Trial22
| Characteristic | Outcome Present, N; Cotinine Means (SD) | Outcome Absent, N; Cotinine Means (SD) | Wilcoxon P Test for Significant Differences in Cotinine Levels, ng/mL |
| Asthma exacerbations on study | 85; 203 (459) | 290; 251 (542) | 0.293 |
| Asthma-related hospitalizations on study | 24; 173 (386) | 351; 245 (532) | 0.338 |
| Delivery < 37 wk | 66; 294 (590) | 309; 229 (509) | 0.547 |
| Delivery < 32 wk | 15; 119 (298) | 360; 245 (531) | 0.557 |
| Oligohydramnios | 21; 36 (153) | 354; 252 (536) | 0.025 |
| Preeclampsia | 31; 187 (452) | 344; 245 (531) | 0.540 |
| PROM | 51; 285 (604) | 324; 233 (511) | 0.688 |
| Perinatal death | Only six cases of perinatal death in RCT | ||
| SGA < 10th percentile | 27; 527 (719) | 345; 220 (502) | 0.035 |
| Abruption | Only two cases of abruption in RCT |